70374-39-9 Usage
Description
Lornoxicam, also known as Xefo, is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class. It possesses analgesic, anti-inflammatory, and antipyretic properties, making it effective for treating various types of acute mild to moderate pain resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica, and rheumatic diseases. Lornoxicam potently inhibits prostaglandin biosynthesis, exhibiting highly pronounced efficacy. Although its exact mechanism is not fully understood, it is known to inhibit prostaglandin and thromboxane synthesis by targeting both COX-1 and COX-2 enzymes, leading to a reduction in inflammation, pain, fever, and swelling.
Uses
Used in Pharmaceutical Industry:
Lornoxicam is used as an analgesic, anti-inflammatory, and antipyretic agent for the management of various types of acute mild to moderate pain, including that resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica, and rheumatic diseases.
Used in Pain Management:
Lornoxicam is used as a pain reliever for postoperative pain, as it is as effective as morphine, meperidine, and tramadol in providing relief.
Used in Arthritis Treatment:
Lornoxicam is used as an anti-inflammatory agent for the treatment of osteoarthritis and rheumatoid arthritis, helping to alleviate symptoms and improve joint function.
Used in Melanin Binding Studies:
Lornoxicam has been utilized in melanin binding studies with cassette dosing and rapid equilibrium dialysis inserts, providing insights into its interaction with melanin.
Used in Migraine Treatment:
Lornoxicam has been found to have inhibitory effects on spinal nocicceptive processing, presumably via the release of endogenous opioids, making it a potential candidate for migraine treatment.
References
https://www.drugbank.ca/drugs/DB06725
https://en.wikipedia.org/wiki/Lornoxicam
Originator
Nycomed Amersham (Norway)
Indications
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that is used as a painkiller (analgesic). A high level of pain relief is experienced by about 45% of those with moderate to severe postoperative dental pain after a single dose of lornoxicam 8 mg, compared to about 10% with placebo. This is comparable to the proportion experiencing the same level of pain relief with ibuprofen 200 to 400 mg. Adverse events were generally mild and did not differ from placebo in these singe dose studies. There were insufficient data to assess duration of action, but it is likely to be similar to ibuprofen 200 mg.
in vitro
studies on intact human cells showed that lornoxicam intensively inhibit cox-1 and cox-2 with the lowest ic50 among a large panel of nsaids tested. similar findings were obtained in the whole blood for cox-1/-2. in addition lornoxicam suppressed no formation in a dose-dependently manner with an ic50 of 65 μm. [2]
in vivo
in vivo studies found that lornoxicam was as effective as comparative nsaids and that 8 mg lornoxicam was more effective than 10 mg morphine as a pain-reliever after oral surgery. orally administration of lornoxicam at 16-24 mg daily was more effective than tramadol at 300 mg daily in pain-alleviating after knee surgery. compared to naproxen, lornoxicam showed higher therapeutic potency and lower gastrointestinal toxicity. this was probably due to the short half-life of lornoxicam as compared to the other oxicams. [3]
IC 50
a potent cox-1 and cox-2 inhibitor with ic50 values of 5 nm and 8 nm, respectively.
references
[1]balfour ja, fitton a and barradell lb. lornoxicam, a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. drugs. 1996 apr; 51(4): 639-57.[2]berg j, fellier h, christoph t, grarup j and stimmeder d. the analgesic nsaid lornoxicam inhibits cyclooxygenase (cox)-1/-2, inducible nitric oxide synthase (inos), and the formation of interleukin (il)-6 in vitro. inflamm res. 1999 jul; 48(7): 369-79.[3]radhofer-welte s and rabasseda x. lornoxicam, a new potent nsaid with an improved tolerability profile. drugs today (barc). 2000 jan; 36(1): 55-76.[4]sharma a, pingle a, and baliga vp. lornoxicam efficacy in acute pain (leap) trial. j indian med assoc. 2008 dec; 106(12): 811-3.
Check Digit Verification of cas no
The CAS Registry Mumber 70374-39-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,3,7 and 4 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 70374-39:
(7*7)+(6*0)+(5*3)+(4*7)+(3*4)+(2*3)+(1*9)=119
119 % 10 = 9
So 70374-39-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
70374-39-9Relevant articles and documents
Synthesis method of high-purity lornoxicam
-
Paragraph 0038-0062, (2021/10/11)
The invention belongs to the technical field of medicine synthesis, and particularly relates to a synthesis method of high-purity lornoxicam. The method comprises the following steps: by taking 6-chloro-4-hydroxy-2-methyl-2-H-thieno [2, 3-e]-1, 2-thiazine carboxylic acid methyl ester-1, 1-dioxide and 2-aminopyridine as raw materials and xylene as a solvent, carrying out distillation reaction, condensing mixed gas obtained by the distillation reaction to obtain condensate, adsorbing methanol in the condensate by adopting a solid acid catalyst, and recycling the adsorbed condensate. According to the invention, the methanol generated by the reaction is distilled out so as to promote the reaction to proceed forwards, and then the methanol is absorbed under the catalysis of H2SO4/MxOy superacid solid acid, so that the xylene returned to the reaction system does not contain methanol, and the coking of the reaction is reduced so as to improve the product quality and yield; and the purity of the prepared lornoxicam is high and can reach 99.9% or above, the solvent amount is reduced, and the method is suitable for industrial production.
